Lignox

Lidocaine Hydrochloride, the active ingredient in Lignox, is a local anesthetic presented as a formulation for oromucosal use. It provides temporary loss of sensation in the oral mucosa for dental procedures, minor surgeries, and relief of oral pain. GNH USA supplies Lignox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lignox, a lidocaine‑based local anesthetic, is applied to the oral mucosa to achieve temporary numbness and pain control. - Oral mucosal anesthesia: provides localized loss of sensation for dental extractions, scaling, and minor oral surgeries. - Treatment of aphthous ulcers: reduces pain and facilitates healing of mouth sores. - Sore throat relief: numbs the oropharyngeal mucosa to alleviate discomfort from inflammation or irritation.

Lignox may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning or tingling at the application site - Mild oral irritation or erythema - Taste alteration or metallic taste - Nausea or mild gastrointestinal upset - Headache

Serious or Rare Side Effects: - Allergic reaction (rash, pruritus, angioedema) - Systemic toxicity (dizziness, seizures, cardiac arrhythmia) - Methemoglobinemia (rare, cyanosis) - Persistent numbness beyond expected duration

When using Lignox, consider the following safety measures. - Patient assessment: evaluate for known lidocaine allergy or hypersensitivity before application. - Dosage control: avoid exceeding the recommended amount to reduce risk of systemic absorption. - Concurrent anesthetics: limit use with other local anesthetics to prevent cumulative toxicity. - Medical conditions: use cautiously in patients with cardiac conduction disorders or severe hepatic impairment. - Pregnancy and lactation: assess risk‑benefit ratio as safety data are limited. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lignox can interact with other substances that affect cardiac conduction or increase systemic lidocaine levels.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiac toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative effect may raise toxicity risk. - Beta‑blockers: may enhance lidocaine’s depressant effect on cardiac conduction. - Diuretics (e.g., furosemide): may alter lidocaine clearance, requiring monitoring.